Improving quality of life
Contract Research Organisation

MAC CLINICAL RESEARCH

HOME
NEWS
RESOURCE LIBRARY
GMP PHARMACY
CAREERS
PATIENTS - JOIN A STUDY
  • ABOUT US

  • SERVICES

  • CLINICAL RESEARCH

  • CASE STUDIES

  • CONTACT US

  • More

    FDA - Guidance For Industry

    August 13, 2013

    |

    WHITE PAPER

     

    A Risk-Based Approach to Monitoring                                                                                                                                                                                        

     

     

    This guidance assists sponsors of clinical investigations in developing risk-based monitoring strategies and plans for investigational studies of medical products, including human drug and biological products, medical devices, and combinations thereof. The overarching goal of this guidance is to enhance human subject protection and the quality of clinical trial data by focusing sponsor oversight on the most important aspects of study conduct and reporting.

     

    This guidance makes clear that sponsors can use a variety of approaches to fulfill their responsibilities for monitoring clinical investigator (CI) conduct and performance in investigational new drug (IND) studies conducted under 21 CFR part 312 or investigational device exemption (IDE) studies conducted under 21 CFR part 812. The guidance describes strategies for monitoring activities that reflect a modern, risk-based approach that focuses on critical study parameters and relies on a combination of monitoring activities to oversee a study effectively. For example, the guidance specifically encourages greater use of centralized monitoring methods where appropriate.

     

    FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Rather, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

     

    This document is displayed here for educational reference purposes only.

     

    The document can be found on the FDA website at the following downloads site address link: 

     

    .

    Please reload

    Top
    Back to News
    Back to Resources
    Featured Posts

    PRESS RELEASE: MAC Clinical Research expands its Global Site Network and access to patients in Australia and Asia Pacific regions

    October 29, 2018

    MAC Opens Phase I Clinic in the Manchester Corridor

    March 2, 2015

    HOT OFF THE PRESS!! - JOBS - CAREERS WITH MAC

    November 25, 2019

    1/8
    Please reload

    Categories

    INNOVATION

    CORPORATE

    EVENTS

    AWARDS

    MEDIA

    REGULATORY

    CAREERS

    Please reload

    • Facebook page
    • Twitter page
    • Instagram page
    • LinkedIn Social Icon
    HOME
    NEWS
    CONTACT US
    SITE MAP
    CAREERS
    FEASIBILITY REQUEST
    RESOURCE LIBRARY
    MEETINGS & CONFERENCES
    PRIVACY AND COOKIE POLICY
    Clinical Trials

    The UK's largest Independent Clinical Development Organisation that owns a network of sites

    Contract Research Organisation

    Copyright © 2019 MAC Research Ltd Group |

    SMO Services Ltd |   All rights reserved